What Is It?
The full 44-amino-acid sequence of human GHRH with one engineered modification. FDA-approved in 2010 under the brand name Egrifta. The most complete growth hormone releasing peptide ever brought to market.
How Does It Work?
Sermorelin sent the first 29 words of the wake-up call. CJC-1295 took those 29 words and made them last longer. Tesamorelin delivered the full 44-word message. Binds the GHRH receptor with a stabilized N-terminus that enables survival to the pituitary. Triggers pulsatile GH release with visceral fat selectivity.
Primary Benefits (research suggests)
- 15-18% visceral fat reduction at 26 weeks (sustained at 52 weeks)
- Spares subcutaneous fat and lean muscle
- Specifically targets the deep abdominal fat tied to cardiovascular disease
Run the Numbers
Calculate your Tesamorelin reconstitution — BAC water volume, syringe units, and draw amounts. Free, no login required.
Open the Calculator →The Honest Part
- FDA-approved only for HIV-associated lipodystrophy — all other use is off-label.
- Requires chronic treatment — fat returns after stopping.
- Carries a hyperglycemia warning.
- WADA prohibited.
- For research purposes only when discussing non-approved uses.
Research Sources
Verified vendors offering this compound for research purposes. Use code ROCN10 for discounts. We may earn commissions from these links.
Track Tesamorelin in the App
Peptide Manager Pro tracks 100+ compounds with an interactive knowledge graph, dosing calculator, protocol tracker, and AI research chat. Veteran-owned. $4.99/mo founding rate.
Get the App →